Precision Medicine Satellite Meeting

The precision medicine satellite meeting, closing this year’s Ilanit conference will host leading world experts, from the various angles of this emerging field.

Precision Medicine (also referred to as personalized medicine) is a rapidly evolving field spanning big data analysis, data sharing, prognostic and predictive biomarkers, combined together to select specific treatments for individual patients. The satellite symposium boasts world leaders in the field and will provide attendees with a comprehensive view of this emerging field of biomedical research which is expected to change the medical world in the near future.

  • The Satellite meeting will take place on Thursday the 23rd starting at 14:15 directly after ILANIT’s closing session, and run until 18:45.
  • Participants registering only for the Satellite meeting are allowed entry to the ILANIT conference from Wednesday after lunch (14:15).
  • Buses and/or flights will be available after the end of the meeting. For more information, please take a look at the Transportation-tab.
Plenary Speakers
atul-butte-pic

Atul Butte

Atul Butte, MD, PhD is the inaugural Director of the Institute of Computational Health Sciences (ichs.ucsf.edu) at the University of California, San Francisco, and a Distinguished Professor of Pediatrics.  Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers.  Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT.   Dr. Butte has authored nearly 200 publications, with research repeatedly featured in Wired Magazine, the New York Times, and the Wall Street Journal.  Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the White House as an Open Science Champion of Change for promoting science through publicly available data.  Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing clinical interpretation of whole genome sequences, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is a principal investigator of three major programs: the California Initiative to Advance Precision Medicine; the California Precision Medicine Consortium, helping recruit tens of thousands of participants into President Obama’s Precision Medicine Initiative; and ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.

matthias-mann-photo-photo

Matthias Mann

Matthias Mann studied physics and mathematics at Göttingen University and obtained his Ph.D. in chemical engineering at Yale where he was decisively involved in the development of electrospray ionization. Thereafter at the University of Southern Denmark he developed the first bioinformatic search algorithms for peptide fragmentation data and SILAC, a new method of quantitative proteomics and a breakthrough in the mapping of protein interactions.

In 2005, he was appointed director at the Max-Planck Institute of Biochemistry in Munich. Here his group addresses a wide range of biological questions developing and using proteomic technology. In 2009 Dr. Mann was additionally appointed director at the NNF Center for Protein Research in Copenhagen.

 

marc-e-rothenberg-pic

Marc E. Rothenberg

Dr. Rothenberg is the Director of the Division of Allergy and Immunology at Cincinnati Children’s Hospital, the Bunning Tenured Chair of Allergy and Immunology, the Founder and Director of the Cincinnati Center for Eosinophilic Disorders, and the Founder and Director of the NIH-sponsored USA Consortium of Eosinophilic Disease Researchers. He graduated summa cum laude in Chemistry and Biochemistry from Brandeis University, and has an MD/PhD in Immunology from Harvard Medical School. His clinical training is in pediatric allergy and immunology.  His research is focused on molecular analysis of allergic inflammation, and has included seminal studies on eosinophil hematopoiesis, which led to the development of a new class of drugs (humanized anti-IL-5). Dr. Rothenberg’s awards include the 2007 E. Mead Johnson Award from the Society of Pediatric Research, an NIH MERIT Award in 2010 and he is a member of the Hewlett-Woodmere Alumni Hall of Fame.  He is an elected member of the ASCI, AAP, AAAS and SPR. His publications number over 350. He is an Associate Editor of the Journal of Allergy and Clinical Immunology, and Mucosal Immunology, and co-Section Head of the Allergy and Hypersensitivity Section of Faculty 1000.  He is the Inventor of over 20 patents.  He has served as a key Consultant to a number of Start-Up Companies that have subsequently become public entities.  He has served a four-year term on the Advisory Council of the NIAID/NIH. His research has been supported by numerous sources including the NIH and US-Israel Binational Fund.

 

kurzrock-photo

Razelle Kurzrock

Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.

At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine.   Dr. Kurzrock received her MD degree from the University of Toronto and has over 650 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building.

Dr. Kurzrock also has a strong history of building outstanding education/training programs.  At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics.  At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.

Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.

yosef-yarden-pic

Yosef Yarden

Born in Israel, Yosef Yarden received his B.Sc. in Biological and Geological Sciences from the Hebrew University of Jerusalem (1980), and a Ph.D. in Molecular Biology from the Weizmann Institute of Science (1985). His postdoctoral training was undertaken at Genentech, Inc. (c/o Axel Ullrich) in San Francisco, and at the Massachusetts Institute of Technology (c/o Robert A. Weinberg). In November 1988, he returned to the Weizmann Institute of Science as an Assistant Professor and was appointed Associate Professor in 1992, and Full Professor in 1996. His past administrative responsibilities at the Weizmann Institute include Dean of the Faculty of Biology (1997-1999), Vice-President for Academic Affairs (1999-2001), Director of the M.D. Moross Institute for Cancer Research (1999-2001), and Dean of the Feinberg Graduate School (2001-2007). From January 2011 till December 2013 he served as President of the Federations of Israel Societies of Experimental Biology (FISEB/ILANIT). Among Yarden’s honors and awards are the Sergio Lombroso Prize in Cancer Research (1994), the Andre Lewoff Prize (1995), the Michael Bruno Memorial Award of Yad Hanadiv (Rothschild Family Prizes; 2000), the TEVA Founders Prize (2004), the MERIT Award of the U.S. National Cancer Institute (2005), the EMET Prize in Biochemistry (2007), the 2008 Hamilton Fairly Award of the European Societies for Medical Oncology (ESMO), the Ernst W. Bertner Memorial Award of the M.D. Anderson Cancer Center (2011), the Susan G. Komen for the Cure® Brinker Award for Scientific Distinction in Basic Research (2012) and Leoplod Griffuel Award of Fondation ARC pour la Recherche sur le Cancer (2015). In 2007, Yarden was elected member of the Israel Academy of Sciences and Humanities.

REGISTER TO ILANIT & PRECISION MEDICINE SATELLITE MEETING!